Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.44
+0.29 (2.21%)
At close: Mar 6, 2026, 4:00 PM EST
13.40
-0.04 (-0.30%)
After-hours: Mar 6, 2026, 7:59 PM EST
Intellia Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 67.67 | 57.88 | 36.28 | 52.12 | 33.05 | |
| Revenue Growth (YoY) | 16.92% | 59.55% | -30.40% | 57.69% | -43.01% | |
| Cost of Revenue | 324.45 | 406.91 | 435.07 | 419.98 | 229.81 | |
| Gross Profit | -256.78 | -349.04 | -398.79 | -367.86 | -196.75 | |
| Selling, General & Admin | 184.21 | 185.23 | 116.5 | 90.31 | 71.1 | |
| Operating Expenses | 184.21 | 185.23 | 116.5 | 90.31 | 71.1 | |
| Operating Income | -440.99 | -534.26 | -515.29 | -458.16 | -267.85 | |
| Interest & Investment Income | 29.2 | 47.81 | 49.83 | 8.54 | 1.28 | |
| Earnings From Equity Investments | - | - | -15.63 | -11.08 | -1.33 | |
| EBT Excluding Unusual Items | -411.8 | -486.46 | -481.09 | -460.7 | -267.89 | |
| Gain (Loss) on Sale of Investments | -0.9 | -32.57 | - | - | - | |
| Other Unusual Items | - | - | -0.1 | -13.49 | - | |
| Pretax Income | -412.69 | -519.02 | -481.19 | -474.19 | -267.89 | |
| Net Income | -412.69 | -519.02 | -481.19 | -474.19 | -267.89 | |
| Net Income to Common | -412.69 | -519.02 | -481.19 | -474.19 | -267.89 | |
| Shares Outstanding (Basic) | 108 | 99 | 89 | 77 | 71 | |
| Shares Outstanding (Diluted) | 108 | 99 | 89 | 77 | 71 | |
| Shares Change (YoY) | 9.64% | 11.35% | 15.33% | 8.57% | 26.63% | |
| EPS (Basic) | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | |
| EPS (Diluted) | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | |
| Free Cash Flow | -395.87 | -354.66 | -408.07 | -346.85 | -237.79 | |
| Free Cash Flow Per Share | -3.65 | -3.59 | -4.60 | -4.51 | -3.35 | |
| Operating Margin | -651.67% | -923.10% | -1420.51% | -879.04% | -810.37% | |
| Profit Margin | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% | |
| Free Cash Flow Margin | -584.99% | -612.78% | -1124.94% | -665.46% | -719.41% | |
| EBITDA | -431.22 | -523.98 | -506.32 | -450.59 | -260.96 | |
| D&A For EBITDA | 9.77 | 10.29 | 8.98 | 7.57 | 6.89 | |
| EBIT | -440.99 | -534.26 | -515.29 | -458.16 | -267.85 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.